EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PTPN2 Inhibition Disrupts Mitochondrial Renewal and Blocks TFRC‐Mediated Mitophagy to Exert Anti‐Tumor Activities in ALK‐Positive Anaplastic Large Cell Lymphoma

Wei-Ting Wang, Zi-Wen Duan, Tong-Yao Xing, Wei Hua, Kai-Xing Du, Chun-Yu Shang, Yi-Fan Wu, Li Wang, Jian-Yong Li, Rui Gao, Jin-Hua Liang, Wei Xu iD

Advanced Science · 2025

DOI: 10.1002/advs.202414282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Wei-Ting Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China. Hauptthemen laut MEDLINE: Lymphoma, Large-Cell, Anaplastic, Mitophagy, Mitochondria, Anaplastic Lymphoma Kinase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Project 333 of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anaplastic large cell lymphoma (ALCL) is a heterogeneous subtype of T‐cell lymphoma usually driven by genetic alterations affecting the anaplastic lymphoma kinase (ALK) gene. Despite the relatively favorable prognosis of ALK‐positive (ALK + ) ALCL, approximately 30–40% of patients experience relapses or disease progression. This work identifies protein tyrosine phosphatase PTPN2 as a critical gene essential for the growth and survival of ALK + ALCL by CRISPR/Cas9 editing. PTPN2 depletion can significantly suppress tumor cell proliferation, induce apoptosis, and provoke cell cycle arrest. Mechanistically, PTPN2 negatively regulates transferrin receptor (TFRC) expression to promote mitochondrial renewal via PTEN induced kinase 1 (PINK1)‐PRKN (parkin RBR E3 ubiquitin protein ligase)‐mediated mitophagy. The process functions independently of ferroptosis. Interestingly, TFRC is directly regulated by the transcription factor hypoxia‐inducible factor 1 alpha (HIF1A) in its promoter. Notably, an orally bioavailable potent PTPN2/N1 active‐site inhibitor ABBV‐CLS‐484 (AC484) demonstrates significant therapeutic potential against ALK + ALCL by disturbing mitochondrial renewal and blocking TFRC‐mediated PINK1‐PRKN‐dependent mitophagy to exert anti‐tumor activities, providing critical insights into the selection of targeted treatment strategies for ALK + ALCL patients and a strong rationale for advancing AC484 into clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large-Cell, AnaplasticMitophagyMitochondriaAnaplastic Lymphoma KinaseProtein Tyrosine Phosphatase, Non-Receptor Type 2HumansAnimalsMiceCell Line, TumorCell Proliferation

Stichwörter der Autor:innen

ABBV‐CLS‐484ALK‐positive anaplastic large cell lymphomaPTPN2TFRCmitophagy

Substanzen

Anaplastic Lymphoma KinaseProtein Tyrosine Phosphatase, Non-Receptor Type 2PTPN2 protein, humanALK protein, human

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
  • Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.
  • Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China.
  • Department of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.

ORCID-Profile: Wei Xu

Förderung

  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • Project 333 of Jiangsu Province
  • Jiangsu Provincial Department of Science and Technology
  • Jiangsu Province Hospital
  • Nanjing Municipal Human Resources And Social Security Bureau

Zitieren

APA

Wang, W. T., Duan, Z. W., Xing, T. Y., Hua, W., Du, K. X., Shang, C. Y., Wu, Y. F., Wang, L., Li, J. Y., Gao, R., Liang, J. H., & Xu, W. (2025). PTPN2 Inhibition Disrupts Mitochondrial Renewal and Blocks TFRC‐Mediated Mitophagy to Exert Anti‐Tumor Activities in ALK‐Positive Anaplastic Large Cell Lymphoma. Advanced Science. https://doi.org/10.1002/advs.202414282

Vancouver

Wang WT, Duan ZW, Xing TY, Hua W, Du KX, Shang CY, et al. PTPN2 Inhibition Disrupts Mitochondrial Renewal and Blocks TFRC‐Mediated Mitophagy to Exert Anti‐Tumor Activities in ALK‐Positive Anaplastic Large Cell Lymphoma. Advanced Science. 2025. doi:10.1002/advs.202414282

BibTeX
@article{Wang2025,
  author = {Wang, Wei-Ting and Duan, Zi-Wen and Xing, Tong-Yao and Hua, Wei and Du, Kai-Xing and Shang, Chun-Yu and Wu, Yi-Fan and Wang, Li and Li, Jian-Yong and Gao, Rui and Liang, Jin-Hua and Xu, Wei},
  title = {PTPN2 Inhibition Disrupts Mitochondrial Renewal and Blocks TFRC‐Mediated Mitophagy to Exert Anti‐Tumor Activities in ALK‐Positive Anaplastic Large Cell Lymphoma},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202414282}
}
Kostenlos starten →